MiMedx Group, Inc

Stage 2 · Advancing · week 3

As of Oct 22, 2026, MiMedx Group is in Stage 2, the uptrend phase, now in week 3 (since Oct 6, 2026). It closed at $3.93, 50.6% below its 52-week high and below its 200-day average, which is falling.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. More about the company

$3.93

+6.22% today

$574M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is MDXG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S4 15w

S4 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 9w → S3 8w → S2 12w → S3 7w → S4 10w → S1 4w → S4 14w → S1 3w → S2 11w → S3 10w → S4 15w → S1 10w → S4 3w → S1 4w → S3 3w → S2 2w → S3 1w → S4 24w → S1 13w → S2 2w current

Total tracked: 165 weeks across 20 stage runs.

MDXG among Biotechnology324th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…324	MDXGMiMedx Group, Inc	Stage 2 · wk 3	27	−17.6%

vs 52W High

-50.6%

$3.09 lo$7.96 hi

50.6% below 52W high

How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.

Stage Maturity

Week 3

1w13w26w

Week 3, fresh breakout

How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.

vs 200 DMA

-9.4%

200 DMA: $4.34 · sloping down

Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.

Rel Volume

1.34x

vs 50-day avg

Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-17.6%

-6.4%

+17.3%

YTD

-39.4%

-41.7%

Scan Membership

Breakout Watch

Latest: 2024-12-05

9 appearances in last 60 days. First seen: 2019-06-21.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S2

Wk 3 · Vol 1.34x

2026-10-21S2

Wk 3 · Vol 1.93x

2026-10-20S2

Wk 3 · Vol 1.43x

2026-10-19S2

Wk 2 · Vol 2.41x

2026-10-16S2

Wk 2 · Vol 2.50x

2026-10-15S2

Wk 2 · Vol 1.22x

2026-10-14S2

Wk 2 · Vol 1.49x

2026-10-13S2

Wk 2 · Vol 0.87x

2026-10-12S2

Wk 1 · Vol 0.54x

2026-10-09S2

Wk 1 · Vol 0.31x

2026-10-08S2

Wk 1 · Vol 0.84x

2026-10-07S2

Wk 1 · Vol 0.64x

Moving averages & range

50 DMA

$4.53

200 DMA

$4.34

52W High

$7.96

52W Low

$3.09

5D Low

$3.70

Resistance levels (recent highs)

20d High

$4.83

60d High

$4.93

120d High

$4.93

250d High

$7.96

Next resistance

+22.9%

to 20d High

P/E (TTM)

98.3

Forward 37.4

ROE

+2.9%

Profit margin +1.8%

Dividend Yield

0.00%

P/B 2.7

MiMedx Group: quick answers

What stage is MiMedx Group in?

As of Oct 22, 2026, MiMedx Group (MDXG) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 6, 2026 and is in week 3. What the four stages mean

Is MiMedx Group in an uptrend?

Yes. MiMedx Group is in a Stage 2 uptrend. It trades 9.4% below its 200-day average, which is falling.

How far is MiMedx Group from its 52-week high?

MiMedx Group closed at $3.93 on Oct 22, 2026, 50.6% below its 52-week high of $7.96. Its 52-week low is $3.09.

How has MiMedx Group performed over the past year?

As of Oct 22, 2026, MiMedx Group is down 41.7% over the past year and down 39.4% so far in 2026.

Which sector and industry is MiMedx Group in?

MiMedx Group is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.